Track topics on Twitter Track topics that are important to you
With annual sales reaching $15 billion in 2010, Medtronic is the 4th largest medical devices company in the world (based on annual sales). The device portfolio of Medtronic is broad; covering card...
The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...
MediciGlobal is a specialty patient recruitment-retention organization serving the clinical trials industry. For more than two decades, the company has led the industry in developing innovative p...
Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace
The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
Galderma is a global company delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime.With more than 5,500 employees, Galderma has three units focus...
One of Galderma's most popular skin care product lines is getting a full graphics and packaging upgrade. read more
David SalazarMirvaso was approved in 2013 as a first-in-class treatment for rosacea-related redness, and according to Galderma it can start working for some patients 30 minutes after application and l...
FDA's OTC division uses the NDAC meeting on Galderma's Differin Gel switch proposal to ask for the advisory committee's input on evaluating future NDAs for other switches that could introduce new risk...
FDA schedules an April 15 NDAC to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.
FDA schedules an April 15 NDAC meeting to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.
David SalazarMiles Harrison joined Galderma U.S. in 2014 from Novartis as VP and general manager, self-medication business unit, which includes Cetaphil. read more
FDA's OTC division uses the NDAC meeting on Galderma's Differin Gel switch proposal to ask for input on evaluating future NDAs for other switches that would introduce new risks to the OTC space.
This article is an historical overview of the Hanau Engineering Company from the time of Rudolph Hanau's death in 1930 to the present. It explores the development of many articulators intended both fo...